TABLE 1.
Characteristics of patients receiving PCZ DRT or OSa
| Characteristic | Value(s) for patients receiving: |
P value | |
|---|---|---|---|
| DRT (n = 48) | OS (n = 13) | ||
| No. (%) men/no. (%) women | 24 (50)/24 (50) | 7 (54)/6 (46) | |
| Mean (IQR) age (yr) | 55 (47.0–64.0) | 49 (29.5–66.0) | NSa |
| Mean (IQR) BMI | 25.2 (21.6–28.0) | 23.7 (21.7–26.0) | NS |
| No. (%) of patients with: | |||
| AML | 31 (65) | 3 (23) | <0.001 |
| ALL | 1 (2) | 4 (31) | NS |
| CLL | 0 | 1 (8) | NS |
| Myelofibrosis | 3 (6) | 0 | NS |
| Diffuse large B-cell lymphoma | 3 (6) | 1 (8) | NS |
| Aplastic anemia | 2 (4) | 0 | NS |
| Others | 8 (17) | 4 (31) | NS |
| HSCT allogeneic | 34 (71) | 8 (62) | 0.039 |
| GVHD presentb | 25 (74) | 5 (63) | <0.001 |
| PPI treatment | 34 (71) | 8 (62) | <0.001 |
| Diarrhea | 12 (25) | 1 (8) | 0.002 |
a
BMI, body mass index; NS, not significant; AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia.
b
The percentages indicate the percentages of patients with GVHD among patients with allogeneic HSCT. Sixty percent of patients receiving DRT and 40% of patients receiving OS had GVHD grade 3 or 4; the rest had GVHD grade 1 or 2.